Hit To Lead

Guiding you from hit validation to lead optimization

The hit to lead phase is critical to drug discovery programs.

At this phase, preliminary preclinical pharmacokinetic and safety assessments of the potential lead molecules are completed both in vitro and in vivo. Lead compounds emerging from this stage exhibit sufficient efficacy and safety profiles to warrant further development—which can help make critical advances in your pharmaceutical discovery program.

Bioisosterism expertise in synthesizing and screening new hits for enhanced absorption, distribution, metabolism and excretion (ADME) properties.

Working with our high-quality trusted research partner network, we can assist you during the hit to lead phase and ensure the generation of high-quality results via a very efficient design, make, test, and analyze (DMTA) cycle. With the support of our lead optimization team, you can efficiently discover and advance successful leads to drug candidates.

A key aspect of Hit-to-Lead success is the need to explore a chemical space rapidly to assess viability of each vector around a scaffold of interest. Agility in establishing efficient and divergent synthetic route brings speed to the project and shortens DMT cycles. This is done efficiently with our late-stage functionalization techniques and our parallel synthesis platforms.

Get in touch

What our clients
say about us

With a wealth of experience, SpiroChem offers clients unparalleled high-quality solutions supported by a world-class team of chemistry experts.

Testimonials

“SpiroChem services have been invaluable with lead optimization, starting with medicinal chemistry advice, following with compound synthesis, and finally reporting. We now have a more comprehensive understanding of the structure-activity relationship and a more solid foundation for our IP. The SpiroChem team are very efficient and deliver excellent quality on time, providing good value for money.”